(0.10%) 5 522.50 points
(0.12%) 39 892 points
(0.23%) 19 797 points
(-0.01%) $81.62
(0.53%) $2.83
(-0.29%) $2 337.50
(0.02%) $29.53
(0.28%) $1 004.60
(0.00%) $0.931
(-0.05%) $10.53
(-0.02%) $0.788
(-0.88%) $87.22
0.02% $ 62.49
Live Chart Being Loaded With Signals
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs)...
Stats | |
---|---|
Dzisiejszy wolumen | 282 719 |
Średni wolumen | 745 490 |
Kapitalizacja rynkowa | 3.75B |
EPS | $-1.180 ( Q3 | 2023-09-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-57.86 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.455 (0.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Viking Global Investors Lp | Sell | 1 743 556 | Common Stock |
2023-09-19 | Redmile Group, Llc | Buy | 498 510 | Common Stock |
2023-09-19 | Redmile Group, Llc | Buy | 494 687 | Common Stock |
2023-09-19 | Redmile Group, Llc | Buy | 864 509 | Common Stock |
2023-09-19 | Redmile Group, Llc | Sell | 498 510 | Series D Preferred Stock |
INSIDER POWER |
---|
-34.91 |
Last 21 transactions |
Buy: 7 015 868 | Sell: 14 005 880 |
Wolumen Korelacja
RayzeBio, Inc. Common Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
RayzeBio, Inc. Common Korelacja - Waluta/Towar
RayzeBio, Inc. Common Finanse
Annual | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.750 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
RayzeBio, Inc. Common
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej